CannBioRx Life Sciences Corp Market Cap ($4.09K)
Market Cap & Net Worth: CannBioRx Life Sciences Corp (ATNFW)
CannBioRx Life Sciences Corp market cap. CannBioRx Life Sciences Corp (NASDAQ:ATNFW) has a market capitalization of $4.09K ($4.09K) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31934 globally and #6432 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CannBioRx Life Sciences Corp's stock price $0.43 by its total outstanding shares 9508 (9.51K). Also see ATNFW cash flow conversion for how efficiently the company converts equity into cash flow.
CannBioRx Life Sciences Corp Market Cap History (2020–2025)
CannBioRx Life Sciences Corp market cap history from 2020 to 2025. Data shows growth from $3.14K to $4.09K (20.13% CAGR). Check today's stock price for CannBioRx Life Sciences Corp for real-time trading data and today's change.
CannBioRx Life Sciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CannBioRx Life Sciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ATNFW year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ATNFW by Market Capitalization
Companies near CannBioRx Life Sciences Corp in the global market cap rankings as of November 4, 2026. Also see CannBioRx Life Sciences Corp (ATNFW) total assets for a full breakdown of the balance sheet.
Key companies related to CannBioRx Life Sciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of CannBioRx Life Sciences Corp (2020–2025)
Market capitalization of CannBioRx Life Sciences Corp from 2020 to today. Between 2020 and today, CannBioRx Life Sciences Corp's market cap moved from $3.14K to $ 4.09K, with a yearly change of 20.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.09K | +4474.47% |
| 2024 | $89.38 | +123.81% |
| 2023 | $39.93 | -92.63% |
| 2022 | $541.96 | -91.86% |
| 2021 | $6.66K | +112.12% |
| 2020 | $3.14K | -- |
End of Day Market Cap According to Different Sources
On Aug 14th, 2026 the market cap of CannBioRx Life Sciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.09K USD |
| MoneyControl | $4.09K USD |
| MarketWatch | $4.09K USD |
| marketcap.company | $4.09K USD |
| Reuters | $4.09K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more